Abstract

The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), is a multistakeholder forum that was established to guide the generation of clinical evidence needed to better inform healthcare treatment and coverage decisions in the United States. GPC members include a diverse mix of payers, life sciences companies, patients, clinicians, researchers, and regulators. GPC convenes working groups to develop condition- and technology-specific study design recommendations that focus on real-world effectiveness and value, meet the evidence expectations of payers, and are informed by the views of patients and clinicians. Participation is by invitation only.

Mission

GPC-USA is a multistakeholder forum established to address the challenge of improving the quality of reimbursement science. GPC-USA develops condition- and technology-specific study design recommendations to guide the generation of evidence needed to inform both clinical and payment decisions. GPC-USA includes a diverse mix of payers, life sciences companies, patients, clinicians, researchers, regulators, and other stakeholders.
Structure & Governance

Advisory Committee:

GPC-International is a partnership between Health Technology Assessment International (HTAi) and CMTP. GPC-International recently completed a pilot project that assessed the feasibility of developing global guidance for the life sciences industry on the design of clinical studies to meet the needs of health technology assessment and coverage bodies.

The Endocrine-Metabolic Consortium, led by C. Daniel Mullins, Ph.D., professor, Pharmaceutical Health Services Research Department (PHSR) at the University of Maryland School of Pharmacy, released its first EGD Recommendations for Late Phase Drug Studies in Type 2 Diabetes in July 2014. This consortium develops methodological standards for research in endocrine and metabolic diseases.

Led by Donna Messner, Ph.D., vice president and senior research director at CMTP, the Oncology Consortium is developing methodologic recommendations and data strategies to help shape research on the best ways to sequence cancer care treatments.

Anne Schott, M.D., who specializes in medical oncology at the University of Michigan, is chairing the Technical Working Group responsible for developing initial recommendations for the GPC’s first EGD, which will identify methods and best practices needed to determine the sequence and timing of multiple “lines” (or combinations) of oncology therapy to yield optimal net benefit to patients. This topic is currently of significance for several types of cancer, including renal cell carcinoma, castration-resistant prostate cancer, and relapse of ovarian cancer.

Homepage

Points of Contact

Center for Medical Technology Policy (CMTP)
World Trade Center Baltimore
401 East Pratt Street, Suite 631
Baltimore, MD 21202
Sponsors & Partners

Aetna Foundation
AstraZeneca
Blue Cross Blue Shield Association
Clovis Oncology
Covidien
Eli Lilly and Company
Foundation Medicine, Inc.
Genentech, Inc.
Genoptix, Inc.
GlaxoSmithKline
Illumina
Laboratory Corporation of America Holdings
M.D.xHealth
Medtronic
Merck & Co.
Millennium: The Takeda Oncology Company
MolecularHealth, Inc.
National Pharmaceutical Council
Novartis Corporation
Pfizer, Inc.
Sanofi US
Thermo Fisher Scientific, Inc.
United Health Foundation

Updated: 04/22/2016